CSL (ASX:CSL) said it will transition its US plasma collection centers to Haemonetics' latest-generation plasmapheresis platform, with the rollout expected to be completed by the end of 2027, according to an Australian bourse filing on Thursday after market hours.
The company has also reached an agreement with Terumo BCT, the provider of its current Rika system, to ensure a smooth transition, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.